Hemogenyx Pharmaceuticals PLC Announces Total Voting Rights
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Hemogenyx Pharmaceuticals (LSE:HEMO), a clinical stage biopharmaceutical company focused on blood and autoimmune disease treatments, has announced its total voting rights as of March 31, 2025. The company's total issued share capital consists of 4,093,539 ordinary shares of 1p each, with none held in treasury.
This figure serves as the denominator for shareholders calculating their notification requirements under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules. The company operates through its US subsidiaries in New York City, where it maintains a state-of-the-art research facility developing several distinct product candidates and platform technologies.
Details
News Market Reaction – HOPHF
The recorded move for HOPHF in the trading session of this news was +75061.30%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LONDON, GB / ACCESS Newswire / March 31, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that the total issued share capital of the Company as at 31 March 2025 consists of 4,093,539 ordinary shares of 1p each, none of which are held in treasury. Therefore, the total number of voting rights in the Company is 4,093,539.
The figure of 4,093,539 ordinary shares may be used by shareholders of the Company as the denominator for the calculations by which they will determine if they are required to notify their investment in, or a change in their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
Enquiries:
Hemogenyx Pharmaceuticals plc |
| |
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder |
| |
Peter Redmond, Director |
| |
SP Angel Corporate Finance LLP |
| Tel: +44 (0)20 3470 0470 |
Matthew Johnson, Vadim Alexandre, Adam Cowl |
|
|
Peterhouse Capital Limited |
| Tel: +44 (0)20 7469 0930 |
Lucy Williams, Duncan Vasey, Charles Goodfellow |
|
|
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.
The Company is a clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Hemogenyx Pharmaceuticals PLC
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.